Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy

Author： Stoof J.C.   Winogrodzka A.   van Muiswinkel F.L.   Wolters E.C.   Voorn P.   Groenewegen H.J.   Booij J.   Drukarch B.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.375, Iss.1, 1999-06, pp. : 75-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cabergoline: A Review of its Efficacy in the Treatment of Parkinson's Disease

By Wiseman L.R.   Fitton A.  

CNS Drugs, Vol. 12, Iss. 6, 1999-12 ,pp. : 485-497

Adis International

Access to resources Recommend Favorite

Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease

By Lemay S.   Chouinard S.   Blanchet P.   Masson H.   Soland V.   Beuter A.   Bedard M.-A.  

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, Iss. 1, 2004-01 ,pp. : 31-39

Elsevier

Access to resources Recommend Favorite

On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?

By  

Current Medicinal Chemistry, Vol. 15, Iss. 23, 2008-10 ,pp. : 2305-2320

Bentham Science Publishers

Access to resources Recommend Favorite

Safinamide in the treatment of Parkinson's disease

By Schapira Anthony HV  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 13, 2010-09 ,pp. : 2261-2268

Informa Healthcare

Access to resources Recommend Favorite

Istradefylline for the treatment of Parkinson's disease

By Park Ariane   Stacy Mark  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 111-114

Informa Healthcare

Access to resources Recommend Favorite